Is IDYA or NUVL more profitable?

IDEAYA Biosciences' return on equity of -14.24% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets IDEAYA Biosciences N/A -14.24% -13.09% Nuvalent N/A -40.11% -35.43%

Does the media prefer IDYA or NUVL?

In the previous week, IDEAYA Biosciences and IDEAYA Biosciences both had 4 articles in the media. Nuvalent's average media sentiment score of 0.72 beat IDEAYA Biosciences' score of 0.47 indicating that Nuvalent is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvalent 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IDYA or KRYS?

In the previous week, Krystal Biotech had 4 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 8 mentions for Krystal Biotech and 4 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.47 beat Krystal Biotech's score of 0.30 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Krystal Biotech 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IDYA or CYTK?

In the previous week, Cytokinetics had 3 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 7 mentions for Cytokinetics and 4 mentions for IDEAYA Biosciences. Cytokinetics' average media sentiment score of 0.85 beat IDEAYA Biosciences' score of 0.47 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytokinetics 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RGC or IDYA?

IDEAYA Biosciences has a consensus target price of $50.69, indicating a potential upside of 37.96%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe IDEAYA Biosciences is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IDEAYA Biosciences 1 Sell rating(s) 1 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.82

Which has higher earnings and valuation, RGC or IDYA?

Regencell Bioscience has higher earnings, but lower revenue than IDEAYA Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A IDEAYA Biosciences $218.71M 14.76 -$113.70M -$1.60 N/A

Is RGC or IDYA more profitable?

Regencell Bioscience's return on equity of 0.00% beat IDEAYA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A IDEAYA Biosciences N/A -14.24% -13.09%

Does the media favor RGC or IDYA?

In the previous week, Regencell Bioscience had 11 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 15 mentions for Regencell Bioscience and 4 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.47 beat Regencell Bioscience's score of 0.08 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral IDEAYA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IDYA or ABVX more profitable?

IDEAYA Biosciences' return on equity of -14.24% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets IDEAYA Biosciences N/A -14.24% -13.09% Abivax N/A -99.02% -70.26%

Does the media refer more to IDYA or ABVX?

In the previous week, IDEAYA Biosciences had 1 more articles in the media than Abivax. MarketBeat recorded 4 mentions for IDEAYA Biosciences and 3 mentions for Abivax. Abivax's average media sentiment score of 0.84 beat IDEAYA Biosciences' score of 0.47 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abivax 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

IDEAYA Biosciences (IDYA) Competitors

$36.74 +0.45 (+1.24%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$35.44 -1.30 (-3.55%)

As of 06/26/2026 06:31 PM Eastern

Compare

IDYA vs. NUVL, KRYS, CYTK, RGC, and ABVX

Should you buy IDEAYA Biosciences stock or one of its competitors? MarketBeat compares IDEAYA Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IDEAYA Biosciences include Nuvalent (NUVL), Krystal Biotech (KRYS), Cytokinetics (CYTK), Regencell Bioscience (RGC), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.

How does IDEAYA Biosciences compare to Nuvalent?

IDEAYA Biosciences (NASDAQ:IDYA) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

IDEAYA Biosciences currently has a consensus price target of $50.69, suggesting a potential upside of 37.96%. Nuvalent has a consensus price target of $127.73, suggesting a potential upside of 3.41%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe IDEAYA Biosciences is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

IDEAYA Biosciences has higher revenue and earnings than Nuvalent. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	14.76	-$113.70M	-$1.60	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

IDEAYA Biosciences' return on equity of -14.24% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Nuvalent	N/A	-40.11%	-35.43%

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by insiders. Comparatively, 5.0% of Nuvalent shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, IDEAYA Biosciences and IDEAYA Biosciences both had 4 articles in the media. Nuvalent's average media sentiment score of 0.72 beat IDEAYA Biosciences' score of 0.47 indicating that Nuvalent is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEAYA Biosciences has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

Summary

IDEAYA Biosciences beats Nuvalent on 9 of the 13 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Krystal Biotech?

IDEAYA Biosciences (NASDAQ:IDYA) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

IDEAYA Biosciences presently has a consensus price target of $50.69, indicating a potential upside of 37.96%. Krystal Biotech has a consensus price target of $340.56, indicating a potential downside of 8.51%. Given IDEAYA Biosciences' higher possible upside, equities analysts plainly believe IDEAYA Biosciences is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Krystal Biotech has a net margin of 53.92% compared to IDEAYA Biosciences' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Krystal Biotech	53.92%	19.25%	17.62%

Krystal Biotech has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	14.76	-$113.70M	-$1.60	N/A
Krystal Biotech	$389.13M	28.20	$204.83M	$7.48	49.77

In the previous week, Krystal Biotech had 4 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 8 mentions for Krystal Biotech and 4 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.47 beat Krystal Biotech's score of 0.30 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Krystal Biotech	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

IDEAYA Biosciences has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

Summary

Krystal Biotech beats IDEAYA Biosciences on 12 of the 16 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Cytokinetics?

IDEAYA Biosciences (NASDAQ:IDYA) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

98.3% of IDEAYA Biosciences shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

IDEAYA Biosciences has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Cytokinetics	-784.02%	N/A	-52.86%

IDEAYA Biosciences has higher revenue and earnings than Cytokinetics. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	14.76	-$113.70M	-$1.60	N/A
Cytokinetics	$88.04M	116.13	-$784.96M	-$6.84	N/A

In the previous week, Cytokinetics had 3 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 7 mentions for Cytokinetics and 4 mentions for IDEAYA Biosciences. Cytokinetics' average media sentiment score of 0.85 beat IDEAYA Biosciences' score of 0.47 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytokinetics	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEAYA Biosciences presently has a consensus target price of $50.69, indicating a potential upside of 37.96%. Cytokinetics has a consensus target price of $100.20, indicating a potential upside of 21.95%. Given IDEAYA Biosciences' higher possible upside, equities analysts plainly believe IDEAYA Biosciences is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

IDEAYA Biosciences has a beta of -0.05, indicating that its stock price is 105% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

Summary

Cytokinetics beats IDEAYA Biosciences on 9 of the 17 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and IDEAYA Biosciences (NASDAQ:IDYA) are both mid-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Regencell Bioscience's return on equity of 0.00% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
IDEAYA Biosciences	N/A	-14.24%	-13.09%

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Regencell Bioscience has higher earnings, but lower revenue than IDEAYA Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
IDEAYA Biosciences	$218.71M	14.76	-$113.70M	-$1.60	N/A

In the previous week, Regencell Bioscience had 11 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 15 mentions for Regencell Bioscience and 4 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.47 beat Regencell Bioscience's score of 0.08 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
IDEAYA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IDEAYA Biosciences has a consensus target price of $50.69, indicating a potential upside of 37.96%. Given IDEAYA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe IDEAYA Biosciences is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82

Regencell Bioscience has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market.

Summary

IDEAYA Biosciences beats Regencell Bioscience on 7 of the 12 factors compared between the two stocks.

How does IDEAYA Biosciences compare to Abivax?

IDEAYA Biosciences (NASDAQ:IDYA) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

IDEAYA Biosciences' return on equity of -14.24% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Abivax	N/A	-99.02%	-70.26%

In the previous week, IDEAYA Biosciences had 1 more articles in the media than Abivax. MarketBeat recorded 4 mentions for IDEAYA Biosciences and 3 mentions for Abivax. Abivax's average media sentiment score of 0.84 beat IDEAYA Biosciences' score of 0.47 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEAYA Biosciences currently has a consensus price target of $50.69, indicating a potential upside of 37.96%. Abivax has a consensus price target of $130.08, indicating a potential upside of 33.41%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe IDEAYA Biosciences is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

IDEAYA Biosciences has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market. Comparatively, Abivax has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

IDEAYA Biosciences has higher revenue and earnings than Abivax. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	14.76	-$113.70M	-$1.60	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

IDEAYA Biosciences beats Abivax on 11 of the 14 factors compared between the two stocks.

Get IDEAYA Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IDYA vs. The Competition

Export

Metric	IDEAYA Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.23B	$3.63B	$7.04B	$12.18B
Dividend Yield	N/A	2.23%	2.66%	6.24%
P/E Ratio	-22.96	21.75	25.90	24.17
Price / Sales	14.76	333.81	600.60	118.47
Price / Cash	N/A	141.14	47.95	55.62
Price / Book	3.15	8.33	10.78	6.36
Net Income	-$113.70M	$23.91M	$3.58B	$337.99M
7 Day Performance	17.64%	3.42%	2.22%	0.10%
1 Month Performance	25.22%	0.39%	-0.09%	-1.28%
1 Year Performance	71.92%	65.22%	34.39%	27.68%

IDEAYA Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IDYA IDEAYA Biosciences	3.3593 of 5 stars	$36.74 +1.2%	$50.69 +38.0%	+71.9%	$3.23B	$218.71M	N/A	80	High Trading Volume
NUVL Nuvalent	2.4485 of 5 stars	$123.36 0.0%	$131.15 +6.3%	+55.0%	$9.75B	N/A	N/A	40	Analyst Downgrade Short Interest Decrease
KRYS Krystal Biotech	2.249 of 5 stars	$341.66 +5.7%	$329.78 -3.5%	+168.0%	$9.53B	$389.13M	45.68	210	Insider Trade High Trading Volume
CYTK Cytokinetics	3.0492 of 5 stars	$78.11 +3.9%	$99.30 +27.1%	+147.8%	$9.36B	$88.04M	N/A	250	Analyst Forecast Insider Trade
RGC Regencell Bioscience	0.3024 of 5 stars	$14.82 -11.4%	N/A	-62.8%	$8.27B	N/A	N/A	10	Analyst Forecast Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IDYA) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IDEAYA Biosciences (IDYA) Competitors

IDYA vs. NUVL, KRYS, CYTK, RGC, and ABVX

How does IDEAYA Biosciences compare to Nuvalent?

Summary

How does IDEAYA Biosciences compare to Krystal Biotech?

Summary

How does IDEAYA Biosciences compare to Cytokinetics?

Summary

How does IDEAYA Biosciences compare to Regencell Bioscience?

Summary

How does IDEAYA Biosciences compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA vs. The Competition

IDEAYA Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IDEAYA Biosciences (IDYA) Competitors

IDYA vs. NUVL, KRYS, CYTK, RGC, and ABVX

How does IDEAYA Biosciences compare to Nuvalent?

Do analysts rate IDYA or NUVL?

Which has stronger valuation and earnings, IDYA or NUVL?

Is IDYA or NUVL more profitable?

Do institutionals & insiders believe in IDYA or NUVL?

Does the media prefer IDYA or NUVL?

Which has more volatility & risk, IDYA or NUVL?

Summary

How does IDEAYA Biosciences compare to Krystal Biotech?

Do institutionals and insiders have more ownership in IDYA or KRYS?

Do analysts recommend IDYA or KRYS?

Is IDYA or KRYS more profitable?

Which has higher earnings and valuation, IDYA or KRYS?

Does the media prefer IDYA or KRYS?

Which has more volatility and risk, IDYA or KRYS?

Summary

How does IDEAYA Biosciences compare to Cytokinetics?

Do institutionals & insiders have more ownership in IDYA or CYTK?

Is IDYA or CYTK more profitable?

Which has higher valuation & earnings, IDYA or CYTK?

Does the media prefer IDYA or CYTK?

Do analysts prefer IDYA or CYTK?

Which has more risk and volatility, IDYA or CYTK?

Summary

How does IDEAYA Biosciences compare to Regencell Bioscience?

Is RGC or IDYA more profitable?

Do institutionals and insiders believe in RGC or IDYA?

Which has higher earnings and valuation, RGC or IDYA?

Does the media favor RGC or IDYA?

Do analysts rate RGC or IDYA?

Which has more risk & volatility, RGC or IDYA?

Summary

How does IDEAYA Biosciences compare to Abivax?

Is IDYA or ABVX more profitable?

Does the media refer more to IDYA or ABVX?

Do analysts rate IDYA or ABVX?

Which has more risk & volatility, IDYA or ABVX?

Which has better valuation & earnings, IDYA or ABVX?

Do institutionals and insiders believe in IDYA or ABVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IDYA vs. The Competition

IDEAYA Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools